Stay updated with breaking news from Jean feyen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Globe Newswire. The AP news staff was not involved in its creation. OXURION NV Presenting Scientific Data at ARVO 2021 Annual Meeting Oxurion NVApril 30, 2021 GMT Leuven, BE, Boston, MA, US – April 30st, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies with a clinical stage portfolio in retinal vascular disorders. Oxurion NV is announcing the presentation of novel scientific data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting which is held on May 1-7, 2021. Professor Alan Stitt, Ph.D., CSO at Oxurion NV comments: ....
OXURION NV Presenting Scientific Data at ARVO 2021 Annual Meeting marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Oxurion NV Business and Financial Update finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year
THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020
The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.
At the end of December 2020, Oxurion had cash, cash equivalents & investments of €24.8 million, allowing the Company to execute on its business plans through the end of Q3 2021. The Company is in advanced discussions with potential investors in order to increase its cash position. ....